Search Bar & Filters
Found 84 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.
Actively Recruiting
Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.
Actively Recruiting
Researchers are evaluating how well active surveillance helps doctors monitor patients with low-risk germ cell tumors after tumor removal. The trial also compares two chemotherapy regimenscarboplatin-based and cisplatin-basedin treating pediatric, adolescent, and young adult patients with standard risk germ cell tumors. This phase III study aims to maintain high survival rates and assess event-free survival, hearing outcomes, body composition effects, and tumor marker correlations. The study includes patients with low-risk stage I germ cell tumors who undergo observation and may transfer to standard risk treatment arms if the tumor recurs. Participants with standard risk non-seminomatous germ cell tumors are randomly assigned to one of four chemotherapy regimens involving bleomycin, etoposide, carboplatin, or cisplatin. Treatments are given intravenously in cycles every 21 days, with up to 3 or 4 cycles depending on the arm and risk group. Throughout the trial, patients undergo imaging scans, blood sample collections, tumor biopsies, and pulmonary function tests to monitor response and side effects. Participants are followed for up to 10 years after treatment completion, with regular visits every 2 months for the first year, then every 3 to 6 months for the next two years, and less frequently thereafter. The study tracks overall survival, event-free survival, hearing loss, patient-reported hearing outcomes, lean body mass, and tumor marker declines. Safety is monitored with tests including audiometry and pulmonary function, and patient questionnaires assess effects such as tinnitus and neuropathy. This long-term follow-up helps evaluate treatment impact and late effects.
Actively Recruiting
Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the addition of a live biotherapy called MO-03 to standard immunotherapy treatments in patients with advanced or metastatic clear cell renal cell carcinoma, a type of kidney cancer that has spread beyond its original site. This phase III trial compares the effects of standard immunotherapy alone versus standard immunotherapy combined with MO-03, which contains beneficial bacteria that may improve gut health and potentially enhance immunotherapy effectiveness. Participants are randomly assigned to one of two groups one group receives MO-03 orally twice daily along with standard immunotherapy regimens tailored by risk level, and the other group receives a placebo along with the same immunotherapy regimens. The immunotherapy regimens include various drugs such as ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, administered intravenously or orally over cycles lasting 42 days, for up to 3 years unless disease progression or unacceptable side effects occur. Throughout the study, participants undergo regular imaging scans like CT or MRI and blood tests to monitor their health and response to treatment. Those with suspected bone or brain metastases may have additional scans. After completing treatment, participants are followed every 6 months for 2 years, then annually for up to 5 years to assess progression-free survival, overall survival, treatment response, and safety. Biological samples are also collected for future research.
Actively Recruiting
Researchers are evaluating whether adding nivolumab to the usual treatment of paclitaxel and ramucirumab improves outcomes for patients with advanced gastric or esophageal adenocarcinoma that has spread locally or to distant sites. This phase IIIII trial aims to compare progression-free survival and overall survival between the combination including nivolumab and the standard regimen without it. The study also assesses response rates, disease control, safety, and quality of life measures to understand the impact of this treatment approach. Participants are randomly assigned to one of two treatment groups. One group receives nivolumab intravenously on day 1, ramucirumab intravenously on days 1 and 15, and paclitaxel intravenously on days 1, 8, and 15 of each 28-day cycle. The other group receives ramucirumab and paclitaxel on the same schedule without nivolumab. Treatment cycles continue every 28 days unless the disease progresses or unacceptable side effects occur. Imaging scans including CT and MRI are performed regularly throughout the study, and optional blood samples may be collected. During the trial, participants undergo assessments including imaging scans and quality of life questionnaires. Follow-up visits occur at 30, 60, and 90 days after treatment ends, then every six months for up to three years. Researchers measure outcomes such as progression-free survival, overall survival, response rates, disease control, and adverse events. Patient-reported symptoms and health-related quality of life are also evaluated to monitor treatment effects and tolerability over time.
Actively Recruiting
Researchers are evaluating whether adding the drug pirtobrutinib to the usual R-CHOP chemotherapy regimen improves treatment outcomes for people with Richter transformation, a condition where chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a faster-growing large B-cell lymphoma. This phase III trial aims to assess safety and effectiveness of this combination compared to R-CHOP alone, with additional goals to investigate genetic mutations associated with the disease and patient-reported symptoms. Participants are randomly assigned to one of two groups. One group receives pirtobrutinib orally daily on days 1 to 21 of each 21-day cycle along with the R-CHOP drugs given intravenously or subcutaneously during 6 cycles, followed by continued pirtobrutinib for up to 5 years if the disease does not progress. The other group receives only the standard R-CHOP treatment for 6 cycles. Pirtobrutinib and R-CHOP drugs include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Some patients may receive an additional treatment cycle if needed. Participants undergo various assessments including heart function tests echocardiography or MUGA scan and imaging scans CT or PETCT throughout the study. Blood and tissue samples are collected for genetic and disease monitoring. Researchers measure progression-free survival, overall survival, response rates, adverse events, and patient-reported symptoms. Follow-up continues for up to 7 years after treatment to monitor long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the impact of adding locoregional treatments such as surgery and radiation, along with metastasis-targeted stereotactic body radiation therapy SBRT, to the usual HER2-targeted systemic therapy for patients with HER2-positive stage IV breast cancer that has spread to other parts of the body or to a limited number of sites oligometastatic. The study compares this multimodal approach to standard systemic therapy alone, aiming to assess overall survival and disease progression outcomes. This phase III trial includes patients whose cancers respond partially or completely to initial systemic therapy and also observes those with stable or progressing disease. Participants first receive standard HER2-targeted systemic treatments for 12 to 24 weeks, possibly including immunotherapy and chemotherapy drugs. Those with a positive response are randomized into two groups one group undergoes surgery and locoregional radiation therapy, followed by SBRT targeting metastatic lesions, then resumes systemic therapy the other group continues systemic therapy alone. Patients without a response continue systemic therapy in an observational cohort. Procedures such as breast conserving therapy or total mastectomy, radiation therapy with or without boost doses, and SBRT are delivered within specific timeframes post initial treatment. Throughout the study, participants undergo various imaging tests including echocardiography ECHO, MRI, mammography, ultrasound, CT, and PETCT scans, with optional biopsies and blood sample collections. Researchers monitor overall survival and progression-free survival for up to 10 years after treatment, with follow-up visits at regular intervals. The study also tracks treatment adherence, disease status, and side effects, aiming to understand the long-term effects of adding locoregional therapies to systemic treatment in this patient group.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the use of olaparib, a PARP inhibitor, as a maintenance treatment following surgery and chemotherapy in patients with pancreatic cancer that has been surgically removed and who have a pathogenic mutation in BRCA1, BRCA2, or PALB2. This phase II randomized trial aims to determine if adding olaparib improves relapse-free survival compared to placebo. The study also explores overall survival and treatment effects based on genetic mutation types and prior chemotherapy regimens. Participants are randomly assigned to receive either olaparib or a placebo taken orally twice daily in 28-day cycles for up to 12 cycles, provided there is no disease progression or unacceptable side effects. Throughout the study, patients undergo CT or MRI scans and have blood samples collected regularly. After completing treatment, patients are followed for up to 10 years with scheduled visits at 30 days post-treatment, every 4 months during the first year, and every 6 months for years 2 through 10. During the trial, participants are closely monitored through imaging and blood tests to assess disease recurrence and overall survival. The primary outcome measures relapse-free survival from randomization up to 44 months, while secondary outcomes include long-term survival and comparisons of treatment effects based on mutation type and chemotherapy received. Safety and disease status are assessed regularly to track treatment impact and progression over an extended follow-up period.
1-10 of 84
1